Clinical Trial Update: Addressing Dementia Via Agitation-Centered Evaluation [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update on agitation in dementia due to Alzheimer's disease investigated by Axsome Therapeutics; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Dementia
• Alzheimer Disease

Drugs mentioned

• Axsome Therapeutics investigational therapy

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-09-13